Nektar OK’d To Test COVID Treatment

Nektar Therapeutics has received FDA approval to test an investigational new drug as a potential treatment for mild COVID-19 cases. Nektar, which is based in California with major facilities in Huntsville and in India, is evaluating its bempegaldesleukin (BEMPEG, NKTR-214) to see whether the drug’s ability to stimulate lymphocyte production could improve treatment of COVID-19…

Thank you for reading!

To continue reading this article you must be registered and logged into this site. If you already have an account please login now, otherwise you can click here to register for new account.

Login       Register

The latest Alabama business news delivered to your inbox